Protagonist Therapeutics, Inc Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Protagonist Therapeutics, Inc stock issued during period, value, new issues for the quarter ending 2023-03-31 was $24.30M, a 66.99% increase year-over-year.
- Protagonist Therapeutics, Inc stock issued during period, value, new issues for the quarter ending 2022-06-30 was $0.00, a 100.00% decline year-over-year.
- Protagonist Therapeutics, Inc stock issued during period, value, new issues for the quarter ending 2022-03-31 was $14.55M.
- Protagonist Therapeutics, Inc stock issued during period, value, new issues for the quarter ending 2021-12-31 was $0.00, a 100.00% decline year-over-year.
- Protagonist Therapeutics, Inc stock issued during period, value, new issues for fiscal 2021 was $123.80M, a 41.87% decline from fiscal 2020.
- Protagonist Therapeutics, Inc stock issued during period, value, new issues for fiscal 2020 was $212.97M.
- Protagonist Therapeutics, Inc stock issued during period, value, new issues for fiscal 2017 was $64.55M, a 22.83% decline from fiscal 2016.
- Protagonist Therapeutics, Inc stock issued during period, value, new issues for fiscal 2016 was $83.65M.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2023-03-31 | $24.30M 10-Q · filed 2023-05-04 | |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $14.56M derived: sum of 4 quarters · filed 2023-05-04 |
| 2022-03-31 | $14.55M 10-Q · filed 2023-05-04 | $138.36M derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $123.80M 10-K · filed 2022-02-28 |
| 2021-09-30 | $6.00K 10-Q · filed 2022-11-08 | |
| 2021-06-30 | $123.80M 10-Q · filed 2022-08-04 | |
| 2020-12-31 | $107.65M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $212.97M 10-K · filed 2022-02-28 |
| 2020-09-30 | -$3.00K 10-Q · filed 2021-11-03 | |
| 2020-06-30 | $105.33M 10-Q · filed 2021-08-04 | |
| 2019-09-30 | $23.95M 10-Q · filed 2019-11-06 | |
| 2019-06-30 | $10.54M 10-Q · filed 2019-08-07 | |
| 2018-09-30 | $1.02M 10-Q · filed 2019-11-06 | |
| 2017-12-31 | $64.55M 10-K · filed 2020-03-10 | |
| 2016-12-31 | $83.65M 10-K · filed 2019-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |